阅读并同意隐私协议、MTA和使用条款后进行下一步!
Cell-free protein synthesis (CFPS) is the most promising and the hardest-to-scale core direction in global synthetic biology over the past seventy years.
No cell culture, direct in vitro synthesis, a production cycle shortened by more than 90%, and a breakthrough beyond the bottlenecks of conventional protein expression — these advantages have long been recognized by academia worldwide.
Yet for more than seventy years, research institutions in Europe and the United States have never solved the scale-up problem. Unstable mass transfer, energy imbalance and by-product inhibition during scale-up have kept CFPS confined to micro-scale laboratory experiments — usable only for small-volume validation in microplates, unable to serve industry or to achieve volume production.
This technological barrier, which stood for seven decades, has been fully broken by Healthcode of China!
From breakthroughs in raw materials at the base layer, to the iteration of production lines, and to independently built dedicated equipment — a full-chain breakthrough. In 2020, Healthcode built the world's first 5-ton-scale D2P cell-free synthesis production line; in 2023, it iterated to 160-ton batch production and entered ten-thousand-ton annual capacity; in 2024, it launched the world's first thousand-liter-scale cell-free synthesis reactor — a historic leap from raw-material mass production to upgraded reaction scale-up, setting a new global record for the industry.
With the launch of the S200 intelligent high-throughput protein synthesis reactor, global cell-free synthesis has officially said farewell to the "micro-scale experiment era".
S200 carries multiple independent reaction vessels and high-throughput reaction channels, supporting flexible volume-gradient experiments and scaled parallel synthesis. With expansion units it can reliably achieve upgraded-scale reactions and gram-level, high-quality eukaryotic protein output.
Built on a purely eukaryotic in vitro system, high-fidelity protein folding, AI-controlled full-parameter regulation and digital full-process traceability, the system eliminates the common failures of conventional systems — poor folding, low activity, poor reproducibility and inability to scale.
Most importantly: the entire system is 100% independently developed, designed and manufactured in China. Hardware, fluidics, algorithms and processes are all localized, fully breaking the overseas technology monopoly.
With this, Healthcode has built the world's only complete cell-free protein synthesis industrial system — from micro-scale research to upgraded pilot scale, to kilogram-level scale-up, to ten-thousand-ton volume production.
This is not merely a breakthrough in one instrument — it is an industrial revolution across the entire field. It ends the industry dilemma abroad of "only bench scale, no volume production; only principles, no engineering", and redefines the global standard for CFPS industrialization.
As the absolute leader and technology benchmark in the global cell-free protein synthesis field, Healthcode supports the rapid development of global AI protein innovation, innovative drug R&D, high-end bio-manufacturing, agricultural biosafety and human health industries with the strength of Chinese science and technology.
A seventy-year global challenge, broken by China in a single stroke! China's bio-manufacturing now leads the world!